Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art Review

Schreiber, TH, Raez, L, Rosenblatt, JD et al. (2010). Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art . Seminars in Immunology, 22(3), 105-112. 10.1016/j.smim.2010.02.001

cited authors

  • Schreiber, TH; Raez, L; Rosenblatt, JD; Podack, ER

abstract

  • Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines. © 2010 Elsevier Ltd.

authors

publication date

  • June 1, 2010

published in

Digital Object Identifier (DOI)

start page

  • 105

end page

  • 112

volume

  • 22

issue

  • 3